Below is a link below to find the latest evidence, from the Trip Database, that we’ve found for you this month:
The evidence is generated from the details you gave us when you registered. If these interests have changed or you want to ‘fine tune’ things you can easily alter your preferences via your profile. If you have any trouble send me an email and I’m sure I’ll be able to help.
Important design news! Coming soon will be the new design to the site; hopefully in the next 4-6 weeks. Further details can be found here.
We’ve been busy on the rapid review work, trying to sort out an appropriate methodology. We’ve had considerable help and we’re getting there. We did a couple of ‘round one’ versions including one onEmpagliflozin in Type 2 Diabetes and we have just published a ‘round two’ review on Brexpiprazole for schizophrenia. This improved methodology includes a meta-analysis. We’re not claiming its perfect but for 60-90 minutes work it’ll generate comparably results to a long-winded (and costly) systematic review and in many cases superior results. It’s an evolving field, and this is an interesting start.
For those who have followed Trip for a long time you’ll have heard mention of an answer engine. We are very close to realising this and we hope to be to demonstrate it in the near future (weeks, not months). The first component is for Trip to automatically infer the underlying question and the second component is then to generate an answer (not just 10-20 search links you currently get now). It uses a variety of techniques including machine learning, semantic annotation and text analysis to find the answers in the Trip Database. Given it relies on the Trip search index it will always be up to date. It will also be available in many languages (for example French, German, Spanish) – no English required. While the initial focus is on therapeutics we will soon be able to add medicines information (drug interactions, side effects etc) and after that we broaden the answers still further. This is revolutionary.
It’s only February and 2016 is starting to look very interesting.